What is the half-life of azithromycin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Azithromycin

The half-life of azithromycin is 68 hours (approximately 2.8 days) in plasma, with complete elimination from the body occurring over 14-20 days (5-7 half-lives). 1

Pharmacokinetic Properties

  • Azithromycin exhibits a polyphasic elimination pattern with a terminal elimination half-life of 68 hours, which is significantly longer than other macrolides like erythromycin (1.5-3 hours) and clarithromycin (3.8 hours) 1, 2

  • The prolonged half-life is attributed to extensive tissue uptake followed by slow release of the drug back into circulation 1

  • In pediatric patients, the half-life appears to be shorter, with some studies reporting values of approximately 3.8 hours after a 10 mg/kg/day dosing regimen for 3 days 3

Tissue Distribution and Concentration

  • Despite relatively low serum concentrations, azithromycin achieves very high tissue concentrations that can exceed serum levels by as much as 100-fold following a single 500 mg oral dose 4

  • The drug concentrates particularly well in:

    • Lung tissue (>100 times plasma concentration)
    • Tonsils (>100 times plasma concentration)
    • Cervix (70 times plasma concentration)
    • Skin (35 times plasma concentration) 1
  • Macrophages and polymorphonuclear leukocytes further concentrate azithromycin at levels greater than those found in the surrounding tissues 4

Clinical Implications of Long Half-Life

  • The extended half-life allows for once-daily dosing and shorter treatment courses (3-5 days) compared to other antibiotics 2

  • For community-acquired pneumonia, the long tissue half-life enables shorter treatment durations of 5-7 days for outpatients and 7-10 days for inpatients 2

  • Single-dose regimens may be effective for certain infections like sexually transmitted diseases due to the prolonged tissue concentrations 5

Important Considerations and Potential Pitfalls

  • The prolonged presence of subinhibitory concentrations (below MIC but above zero) may create a "selective window" for development of bacterial resistance 2

  • Complete elimination from the body takes 14-20 days (5-7 half-lives), during which time subinhibitory concentrations may persist 2

  • A study in healthy volunteers found measurable plasma levels (>5 μg/L) for 7-17 days after a standard 3-day regimen, with elimination half-life ranging from 49-108 hours 6

  • The long half-life and tissue persistence should be considered when evaluating potential drug interactions or when starting new medications within several weeks of azithromycin therapy 1

  • In patients with severe renal impairment (GFR <10 mL/min), the AUC increases by 35% compared to patients with normal renal function, though no dosage adjustment is specifically recommended in the drug labeling 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The pharmacokinetics of azithromycin and their clinical significance.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1991

Research

The pharmacokinetics of azithromycin in human serum and tissues.

The Journal of antimicrobial chemotherapy, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.